Milestone Pharmaceuticals Reports Q4 2025 Results, CARDAMYST™ Update

Milestone Pharmaceuticals has released its fourth quarter and full year 2025 financial results, alongside an update on the commercial launch of CARDAMYST™ (etripamil) nasal spray. The FDA approval of CARDAMYST™ marks a significant advancement, offering the first new treatment option in three decades for paroxysmal supraventricular tachycardia (PSVT). This development is crucial for the over two million patients affected by the condition. The company's focus is now on the successful market introduction and patient access to this innovative therapy, aiming to improve treatment outcomes.